Secondary Hyperparathyroidism Due to Renal CausesNCT07151664
Retrospective Analysis of Quality of Life Changes in Patients Undergoing Parathyroidectomy for End-Stage Renal Disease
An observational study of Secondary Hyperparathyroidism Due to Renal Causes and End Stage Renal Failure, run by West China Hospital.
Trial summary
The purpose of this study is to characterize changes in quality of life in patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease, based on data extracted from an established database Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Secondary Hyperparathyroidism Due to Renal Causes, End Stage Renal Failure
- What is being tested?
- Quality of life progression after parathyroidectomy
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 5 Sep 2025to 20 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease were included in this study
Who may be able to join
- Age ≥18 years； Patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease.
Who cannot join
- Patients who underwent kidney transplantation during the study period. Patients with postoperative whole blood parathyroid hormone levels >300 pg/mL within the first week after surgery.
- Patients with missing postoperative quality of life assessment data.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Quality of Life Change in Patients Undergoing Parathyroidectomy With Secondary Hyperparathyroidism Due toEnd-stage Renal Failure: a Retrospective Cohort Study
The purpose of this study is to characterize changes in quality of life in patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease, based on data extracted from an established database
Read the detailed description
Data were retrospectively collected from an established database of patients who underwent surgery for renal secondary hyperparathyroidism (SHPT). Extracted information included demographic and clinical characteristics (age, gender, education level, clinical symptoms), baseline quality of life assessed by the 36-item Short-Form Health Survey (SF-36), and completed follow-up assessments of SF-36 scores, depression, and anxiety at one, three, six months, and one year postoperatively.
- Being tested
- Quality of life progression after parathyroidectomy
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality of life progression after parathyroidectomyOther
Study the progression of quality of life
| Study group | Role | What they receive |
|---|---|---|
| Quality of life change in patients Undergoing Parathyroidectomy with end-stage renal failure | Quality of Life Progression in PatientsUndergoing Parathyroidectomy WithSecondary Hyperparathyroidism Due to End-stage Renal Failure Receives: Other: Quality of life progression after parathyroidectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of life scores change with respect to time
Quality of life was assessed using the 36-item Short Form Health Survey (SF-36) scale. Completed responses for each of the 36 items were extracted from the database. Item responses were aggregated to calculate scores for each of the eight dimensions. Scores for each dimension range from 0 to 100, with higher scores indicating better health status
Measured: up to 1 year
Secondary outcomes (3)
Anxiety and depression score change with respect to time
Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS). Completed responses for the 14-item HADS, comprising 7 items each for the anxiety (HADS-A) and depression (HADS-D) subscales, were extracted from the database. Item scores range from 0 to 3, and were summed to yield separate scores for anxiety and depression
Measured: up to 1 year
Bone pain scores change with respect to time
Bone pain was evaluated using the Numerical Rating Scale (NRS). Completed NRS scores, ranging from 0 to 10, were extracted from the database. In this scale, 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, 7-9 represents severe pain, and 10 represents the worst pain
Measured: up to 1 year
Length of hospital stay
Measured: an average of 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2025
- Study start5 Sep 2025 (estimated)
- Primary completion5 Dec 2025 (estimated)
- Study completion20 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Secondary Hyperparathyroidism Due to Renal CausesStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chunling Jiang, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07151664
- Sponsor's protocol ID
- 2024804
- Status last verified
- Aug 2025
- First submitted
- 25 Aug 2025
- Last updated
- 3 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quality of Life Change in Patients Undergoing Parathyroidectomy With Secondary Hyperparathyroidism Due toEnd-stage Renal Failure: a Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07151664
- Acronym / sponsor ID
- 2024804
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 5 Sep 2025 (estimated)
- Primary completion
- 5 Dec 2025 (estimated)
- Study completion
- 20 Dec 2026 (estimated)
- First posted
- 3 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to characterize changes in quality of life in patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease, based on data extracted from an established database
Detailed description
Data were retrospectively collected from an established database of patients who underwent surgery for renal secondary hyperparathyroidism (SHPT). Extracted information included demographic and clinical characteristics (age, gender, education level, clinical symptoms), baseline quality of life assessed by the 36-item Short-Form Health Survey (SF-36), and completed follow-up assessments of SF-36 scores, depression, and anxiety at one, three, six months, and one year postoperatively.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Quality of life change in patients Undergoing Parathyroidectomy with end-stage renal failure | – | Other: Quality of life progression after parathyroidectomyQuality of Life Progression in PatientsUndergoing Parathyroidectomy WithSecondary Hyperparathyroidism Due to End-stage Renal Failure |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease were included in this study
Key inclusion criteria (1 listed)
- Age ≥18 years； Patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease.
Key exclusion criteria (2 listed)
- Patients who underwent kidney transplantation during the study period. Patients with postoperative whole blood parathyroid hormone levels >300 pg/mL within the first week after surgery.
- Patients with missing postoperative quality of life assessment data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quality of life progression after parathyroidectomyStudy the progression of quality of life | Other | Quality of life change in patients Undergoing Parathyroidectomy with end-stage renal failure |
Primary outcome
Quality of life scores change with respect to time
Time frame: up to 1 year
Quality of life was assessed using the 36-item Short Form Health Survey (SF-36) scale. Completed responses for each of the 36 items were extracted from the database. Item responses were aggregated to calculate scores for each of the eight dimensions. Scores for each dimension range from 0 to 100, with higher scores indicating better health status
3 secondary outcomes
Anxiety and depression score change with respect to time
Time frame: up to 1 year
Bone pain scores change with respect to time
Time frame: up to 1 year
Length of hospital stay
Time frame: an average of 1 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Secondary Hyperparathyroidism Due to Renal Causes and End Stage Renal Failure, run by West China Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chunling Jiang, PhD (+862885423593, jiangchunling@scu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of life scores change with respect to time (time frame: up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.